康希诺生物在2024年实现了显著的业绩改善,营业收入同比增长137.01%至8.46亿元,归母净亏损收窄74.45%至3.79亿元。这一变化主要得益于新冠疫苗相关资产减值损失的大幅减少。此前,由于新冠疫情的影响逐渐减弱,新冠疫苗需求下降,康希诺在2022年和2023年分别计提了高额的资产减值损失,导致连续两年出现大额亏损。然而,通过两年时间的努力,公司已基本消化了新冠疫苗带来的负面影响。目前,流脑...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.